May 27, 2026

He Raised $70M to Cure Every Disease With AI

Samuel Rodriques, founder of Edison Scientific, shares his journey from physics to building an AI scientist named Kosmos. He discusses how AI agents are already making novel discoveries, including a potential cure for blindness, and are poised to revolutionize drug discovery. The conversation dives into AI's strengths in high-throughput reasoning, the critical bottlenecks in clinical trials, proposed reforms for the US medical system, and whether human scientists will still be needed in an age of hyper-intelligent AI.

Apr 29, 2026

Demis Hassabis on Building DeepMind, AlphaFold, and the Final Stretch to AGI

Demis Hassabis, CEO of Google DeepMind, outlines the path to AGI, which he predicts by 2030. He discusses the profound impact of AI on science, particularly in revolutionizing drug discovery with systems like AlphaFold, and posits that AI will enable new forms of simulation-based science. Hassabis also delves into the philosophical underpinnings of his work, viewing information as the universe's most fundamental quantity and advocating for developing AGI as a powerful tool before tackling the deeper questions of consciousness.

Apr 16, 2026

Episode 16: Building AI for Life Sciences

OpenAI research lead Joy Jiao and product lead Yunyun Wang detail the development of specialized AI models for the life sciences. They discuss the new biochemistry-focused model series designed to accelerate research in genomics and protein understanding, the critical challenge of managing biosecurity risks through a "differentiated access" model, and the future vision of AI-powered autonomous labs that could revolutionize drug discovery and personalized medicine.

Nov 13, 2025

No Priors Ep. 140 | With Benchling Co-Founder and CEO Sajith Wickramasekara

Sajith Wickramasekara, CEO of Benchling, discusses the broken economics of drug development, where high costs and failure rates stifle innovation. He explains how the biotech industry is facing a 'dot com' bust and new competition from China, and argues that AI agents and simulation can provide the solution by making science less artisanal and helping scientists create better molecules through faster, cheaper experiments.

Oct 20, 2025

Introducing Claude for Life Sciences

Anthropic's Jonah Cool and Eric Kauderer-Abrams outline their vision for making Claude an indispensable AI research assistant for scientists. They discuss a multi-faceted strategy that includes enhancing model capabilities for long-horizon tasks, building a rich ecosystem through partnerships with companies like Benchling and 10x Genomics, and applying Claude across the entire R&D lifecycle—from bioinformatics analysis to navigating regulatory submissions.

Oct 20, 2025

How AbbVie accelerates drug discovery with Claude

Sarah Nam, VP of AI Strategy and Partnerships at AbbVie, and Anthropic’s Ivy Weng discuss how AbbVie is transforming pharmaceutical research and development with AI, from reimagining drug discovery and clinical trials to driving enterprise-wide adoption and evaluating strategic partnerships.